Media Articles Related to Ampyra (Dalfampridine)
Multiple Sclerosis May Rebound When Patients Stop Fingolimod
Source: Medscape NeurologyHeadlines [2016.08.19]
In this viewpoint, Dr Barclay discusses a series of five patients with rebound whose cases were consistent with others in the literature.
Multiple Sclerosis (MS) Symptoms, Treatment
Source: MedicineNet Constipation Specialty [2016.08.03]
Title: Multiple Sclerosis (MS) Symptoms, Treatment
Created: 11/3/2010 12:50:00 PM
Last Editorial Review: 8/3/2016 12:00:00 AM
Changes uncovered in the gut bacteria of patients with multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2016.07.14]
Study finds alterations in the gut microbiomes of treated and untreated MS patients.
Could the gut microbiome be a new therapeutic target for multiple sclerosis?
Source: Multiple Sclerosis News From Medical News Today [2016.07.08]
An increasing number of clinical studies are pointing to a link between the autoimmune disease multiple sclerosis (MS) and the composition of microbes in the human gut, sparking new research on the...
New treatment authorised in UK for relapsing forms of multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2016.07.07]
Once-monthly, self-injected treatment offers new option for people living with active disease.
Published Studies Related to Ampyra (Dalfampridine)
Dalfampridine extended release: in multiple sclerosis. [2010.10.01]
Dalfampridine extended release (ER) is an orally administered formulation of dalfampridine (fampridine, 4-aminopyridine), a potassium channel antagonist indicated for the improvement in walking ability in patients with multiple sclerosis (MS). Oral dalfampridine ER improved walking ability in patients with MS in three randomized, double-blind trials of up to 15 weeks' duration...
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. [2010.10]
OBJECTIVE: A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended-release dalfampridine (4-aminopyridine) 10mg twice daily. The current study was designed to confirm efficacy and further define safety and pharmacodynamics... INTERPRETATION: This interventional study provides class 1 evidence that dalfampridine extended-release tablets produce clinically meaningful improvement in walking ability in a subset of people with MS, with the effect maintained between doses.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. 
to confirm efficacy and further define safety and pharmacodynamics... INTERPRETATION: This interventional study provides class 1 evidence that
Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. [2011.07]
BACKGROUND: Multiple sclerosis (MS) can cause progressive walking impairment that contributes to disability, loss of independence, and reduced quality of life. Dalfampridine (4-aminopyridine), a voltage-dependent potassium channel blocker, has been shown to improve walking in patients with MS, as demonstrated by an increase in walking speed. OBJECTIVE: To summarize knowledge about the mechanism of action of dalfampridine in the context of clinical evidence of walking improvement in MS patients... CONCLUSIONS: The extended-release formulation of dalfampridine has been shown in clinical trials to improve walking speed in approximately one third of MS patients with ambulatory impairment. The putative mechanism of action of dalfampridine is restoration of action potential conduction via blockade of an as yet uncharacterized subset of potassium channels in demyelinated axons.
Treatment of walking impairment in multiple sclerosis with dalfampridine. [2011.03]
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been studied most extensively in MS and other demyelinating neurologic disorders...
Clinical Trials Related to Ampyra (Dalfampridine)
Ampyra for Optic Neuritis in MS [Completed]
Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the
hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery
after optic neuritis from MS, will result in symptomatic improvement in visual function. The
study will consist of one screening/baseline visit, one visit during treatment with active
drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned
to receive study medication or placebo for the first three weeks, followed by a two week
wash-out, and then treatment reallocation for the latter three weeks.
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) [Active, not recruiting]
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have
had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease [Completed]
The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in
Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in
multiple sclerosis. There are multiple studies to suggest that persons with multiple
sclerosis benefit from this medication and have major improvements in gait after taking this
medication. However, this medication was never studied in Parkinson's disease. This study
aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) [Completed]
The purpose of this study is to determine changes on overall gait as well as in multiple
gait and balance parameters after withdrawal of dalfampridine-ER 10mg in MS subjects who are
receiving the medication consistently for at least two weeks prior to screening.
A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers [Completed]
Reports of Suspected Ampyra (Dalfampridine) Side Effects
Gait Disturbance (64),
Urinary Tract Infection (63),
Inappropriate Schedule of Drug Administration (57),
Multiple Sclerosis Relapse (52),
Nausea (37), more >>